Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chr… Read more
Incyte Corporation (INCY) - Total Liabilities
Latest total liabilities as of December 2025: $1.80 Billion USD
Based on the latest financial reports, Incyte Corporation (INCY) has total liabilities worth $1.80 Billion USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Incyte Corporation - Total Liabilities Trend (1993–2025)
This chart illustrates how Incyte Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Incyte Corporation Competitors by Total Liabilities
The table below lists competitors of Incyte Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Corem Property Group AB (publ)
ST:CORE-D
|
Sweden | Skr36.64 Billion |
|
FinecoBank Banca Fineco S.p.A
PINK:FNBKY
|
USA | $33.11 Billion |
|
Magna International Inc
NYSE:MGA
|
USA | $19.95 Billion |
|
Super Micro Computer Inc
NASDAQ:SMCI
|
USA | $21.01 Billion |
|
Swisscom AG
PINK:SWZCF
|
USA | $24.31 Billion |
|
Domino’s Pizza Inc
NYSE:DPZ
|
USA | $5.75 Billion |
|
RBC Bearings Incorporated
NYSE:RBC
|
USA | $1.88 Billion |
|
Public Bank Bhd
KLSE:1295
|
Malaysia | RM495.14 Billion |
Liability Composition Analysis (1993–2025)
This chart breaks down Incyte Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Incyte Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Incyte Corporation (1993–2025)
The table below shows the annual total liabilities of Incyte Corporation from 1993 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.80 Billion | -9.68% |
| 2024-12-31 | $2.00 Billion | +25.40% |
| 2023-12-31 | $1.59 Billion | +8.25% |
| 2022-12-31 | $1.47 Billion | +26.43% |
| 2021-12-31 | $1.16 Billion | +22.50% |
| 2020-12-31 | $949.65 Million | +14.64% |
| 2019-12-31 | $828.34 Million | +15.08% |
| 2018-12-31 | $719.79 Million | +7.12% |
| 2017-12-31 | $671.95 Million | -44.88% |
| 2016-12-31 | $1.22 Billion | +45.78% |
| 2015-12-31 | $836.28 Million | -4.76% |
| 2014-12-31 | $878.11 Million | +6.74% |
| 2013-12-31 | $822.68 Million | +62.78% |
| 2012-12-31 | $505.38 Million | -9.11% |
| 2011-12-31 | $556.04 Million | -3.84% |
| 2010-12-31 | $578.23 Million | -29.03% |
| 2009-12-31 | $814.77 Million | +79.81% |
| 2008-12-31 | $453.14 Million | +4.12% |
| 2007-12-31 | $435.21 Million | -0.75% |
| 2006-12-31 | $438.51 Million | +11.44% |
| 2005-12-31 | $393.50 Million | -10.24% |
| 2004-12-31 | $438.40 Million | +94.66% |
| 2003-12-31 | $225.21 Million | -9.82% |
| 2002-12-31 | $249.73 Million | -5.89% |
| 2001-12-31 | $265.36 Million | +0.47% |
| 2000-12-31 | $264.13 Million | +411.87% |
| 1999-12-31 | $51.60 Million | +1.78% |
| 1998-12-31 | $50.70 Million | -5.06% |
| 1997-12-31 | $53.40 Million | +146.08% |
| 1996-12-31 | $21.70 Million | +97.27% |
| 1995-12-31 | $11.00 Million | +134.04% |
| 1994-12-31 | $4.70 Million | +213.33% |
| 1993-12-31 | $1.50 Million | -- |